Nuclear IRF-1 expression as a mechanism to assess “Capability” to express PD-L1 and response to PD-1 therapy in metastatic melanoma
James W. Smithy(Yale University), David L. Rimm(Yale University)
Cited by 43
Related Papers
Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer
|JAMA Oncology|2015|834
PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer
|Cancer Immunology Research|2014|391
Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer
|Modern Pathology|2016|166
Ki67 reproducibility using digital image analysis: an inter-platform and inter-operator study
|Laboratory Investigation|2018|138
Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations
|Journal of Thoracic Oncology|2018|111